The GLP-1 Compounding Crackdown: OFA v. FDA and What Comes Next
Market snapshot: The Outsourcing Facilities Association lost both district court challenges to the FDA's shortage resolutions. The Fifth Circuit heard oral arguments on March 30, 2026 — a decision is pending. Meanwhile, the FDA proposed on April 30 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized, large-scale compounding of these drugs has no regulatory future.
If you're currently taking compounded semaglutide or tirzepatide, the legal and regulatory landscape has shifted dramatically since 2024. Here's a clear timeline of what happened, where things stand today, and what the remaining pathways look like.
The Legal Timeline
Tirzepatide: The First Domino
October 2024: FDA declared the tirzepatide shortage resolved. The OFA and FarmaKeio Custom Compounding sued the same day, arguing the decision was "reckless and arbitrary."
March 5, 2025: Judge Mark Pittman (N.D. Texas) denied OFA's preliminary injunction. Ruling filed under seal.
February 18, 2025: 503A enforcement discretion expired — state-licensed pharmacies could no longer compound tirzepatide copies.
March 19, 2025: 503B enforcement discretion expired — outsourcing facilities lost their window too.
May 7, 2025: Judge Pittman granted summary judgment for the FDA and Eli Lilly. Case dismissed with prejudice.
Semaglutide: The Second Front
February 21, 2025: FDA declared semaglutide shortage resolved. OFA sued again.
April 25, 2025: Judge Pittman denied OFA's PI motion for semaglutide.
May 22, 2025: Enforcement discretion expired for both 503A and 503B compounders.
June 18, 2025: Final judgment entered — dismissed with prejudice. OFA appealed to Fifth Circuit.
The Fifth Circuit: Pending
March 30, 2026: The Fifth Circuit heard oral arguments in both cases. The judges probed whether the FDA's shortage delisting was a "rule" requiring notice-and-comment rulemaking (which would favor the compounders) or an "adjudication" within FDA's existing authority (which would favor the agency). Both sides agreed the shortage is factually over.
⚠️ Important: The Fifth Circuit has not yet ruled. If it sides with the compounders on procedural grounds, it could potentially require the FDA to re-run the delisting through a formal rulemaking process. This would not automatically revive compounding — but it would create temporary legal ambiguity.
The 503B Bulks List: The Kill Shot
On April 30, 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. This is separate from the shortage litigation — and potentially more consequential.
Under current law, 503B outsourcing facilities can compound drugs either because they're on the shortage list or because they're on the 503B Bulks List (which signifies "clinical need"). With the shortage resolved and the Bulks List exclusion proposed, both pathways would be closed simultaneously.
Key details from the FDA's 41-page Federal Register notice:
- The agency found "no clinical need" for outsourcing facilities to compound these drugs from bulk API
- The FDA explicitly rejected affordability and insurance access as constituting clinical need
- Buccal and sublingual formulations were also rejected — the FDA found no basis to conclude that approved oral and injectable routes are "medically unsuitable"
- Public comment period runs through June 29, 2026
If the 503B Bulks List exclusion is finalized, large-scale compounding of semaglutide, tirzepatide, and liraglutide is permanently foreclosed — even if a future shortage occurs. This is the structural end of the compounded GLP-1 era at industrial scale.
What's Still Legal: The 503A Pathway
Patient-specific compounding under Section 503A remains legal — but the pathway is narrow:
- Must be prepared by a state-licensed pharmacy for an individual patient with a valid prescription
- Must demonstrate documented medical necessity (not cost savings)
- Cannot be an "essentially a copy" of a commercially available drug
- Adding B12 or B6 does not automatically avoid "essentially a copy" status per FDA's April 2026 guidance
The FDA clarified in April 2026 that a compounded product combining semaglutide with vitamin B12 is still considered "essentially a copy" if it uses the same route of administration and the strengths are within 10% of commercial products.
The Enforcement Landscape
The FDA has escalated steadily:
- 50+ warning letters sent to compounders and telehealth distributors during 2025
- 30 additional warning letters sent to telehealth companies on March 3, 2026
- 1,150+ adverse event reports linked to compounded sema and tirz by July 2025, with approximately 10 deaths potentially connected
- Hims & Hers pulled back from compounded GLP-1s after FDA pressure and a new partnership with Novo Nordisk
- Eli Lilly sued 12 compounding pharmacies in August 2025 and multiple telehealth providers in early 2026
What This Means for Patients Today
If you're currently on compounded GLP-1 medication from a verified provider operating under 503A with documented medical necessity, your access may continue — but supply continuity is not guaranteed. If your provider loses access or faces enforcement action, you should have a transition plan in place.
The brand-name landscape has also changed dramatically: the Wegovy pill ($149/mo starter), Foundayo ($149/mo starter), and the Medicare GLP-1 Bridge ($50/mo starting July 2026) have created new affordable pathways that didn't exist a year ago.
Compare Verified Providers
Embody
$149 first month / $299 refills
Injectable semaglutide from verified 503A pharmacies. Physician-supervised.
Learn More Paid linkCompounded medications are not FDA-approved.
Gala GLP-1
$179/mo flat
Transparent pricing. No dose-tier increases at any level.
Learn More Paid linkCompounded medications are not FDA-approved.
Sesame Care
Brand-Name GLP-1s
For patients who prefer the FDA-approved pathway. Wegovy, Zepbound, Foundayo.
Learn More Paid linkCompare All GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- OFA v. FDA, No. 4:24-cv-01030 (N.D. Tex.). Court filings and orders.
- OFA v. FDA, No. 4:25-cv-00174 (N.D. Tex.). Court filings and orders.
- Fifth Circuit oral arguments, March 30, 2026. Courthouse News Service.
- FDA Federal Register Notice, 91 Fed. Reg. 23431, April 30, 2026.
- FDA press release: 503B Bulks List proposal, April 30, 2026.
- FDA: Clarification on compounding policies for GLP-1 products, April 2026.
- FDA adverse event data: compounded semaglutide and tirzepatide reports, July 2025.
- Foley & Lardner: FDA compounding policy clarification analysis, April 2026.
Affiliate Disclosure: Some links on this page are paid affiliate links. If you sign up through them, we may earn a commission at no extra cost to you. This does not influence our editorial content or sourcing.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo) carry FDA approval for their indicated uses.